Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
boston blog main
4
×
boston top stories
clinical trials
life sciences
national blog main
national top stories
new york blog main
new york top stories
novartis
4
×
amgen
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alder biopharmaceuticals
alnylam pharmaceuticals
bristol-myers squibb
cancer
cell therapy
deals
diagnostics
eli lilly
fda
fremanezumab
What
drug
4
×
new
4
×
approval
bio
brings
fda
medicines
roundup
acquire
advantages
agreed
amgen
bar
billion
biogen’s
biopharmaceutical
candidates
cash
cholesterol
class
companies
company
compound
convo
deal
developed
earlier
expect
failures
gamble
gets
head
littered
market
medco
medco’s
migraine
mover
nash
news
Language
unset
Current search:
drug
×
biotech
×
novartis
×
" boston blog main "
×
new
×
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines